INKT Insider Trading

Insider Ownership Percentage: 13.21%
Insider Buying (Last 12 Months): $4,440.87
Insider Selling (Last 12 Months): $0.00

MiNK Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at MiNK Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MiNK Therapeutics Share Price & Price History

Current Price: $2.15
Price Change: Price Decrease of -0.06 (-2.71%)
As of 10/6/2022 05:16 PM ET

This chart shows the closing price history over time for INKT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

MiNK Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/18/2022Ulf WiinbergDirectorBuy3,339$1.33$4,440.87281,639View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for MiNK Therapeutics (NASDAQ:INKT)

1.07% of MiNK Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

MiNK Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2022Renaissance Technologies LLC25,760$58K0.0%-26.6%0.077%Search for SEC Filing on Google Icon
2/15/2022Sofinnova Investments Inc.345,499$1.54M0.1%N/A1.031%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
MiNK Therapeutics logo
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More on MiNK Therapeutics

Today's Range

Now: $2.15
Low: $2.08
High: $2.29

50 Day Range

MA: $2.22
Low: $1.24
High: $3.40

52 Week Range

Now: $2.15
Low: $1.09
High: $22.16


60,250 shs

Average Volume

200,377 shs

Market Capitalization

$72.16 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of MiNK Therapeutics?

MiNK Therapeutics' top insider shareholders include:
  1. Ulf Wiinberg (Director)
Learn More about top insider investors at MiNK Therapeutics.
Reclusive trader scores 20 years of winning trades. Learn how.
He had 20 straight years of winning trades without a single losing year… He had 20 straight years of winning trades without a single losing year…

And now, he is coming forward to share a brand-new forecast.
Click here to watch the video now.